CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden.
Frequently asked questions
What sector does Combigene AB (COMBI) operate in?
Combigene AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Combigene AB (COMBI) current stock price?
As of the latest data, Combigene AB stock price is SEK 2.37, with a previous close of SEK 2.37.
What is Combigene AB (COMBI) current market capitalization?
Combigene AB market cap is approximately 46.93 million.
What is Combigene AB (COMBI) Earnings Per Share (EPS)?
The trailing EPS is -SEK 2.27.
Does Combigene AB (COMBI) pay dividends?
No. Combigene AB does not pay a dividend.
What is Combigene AB (COMBI) beta (volatility) score?
Combigene AB has a beta of 1.219, suggesting it is more volatile than the market.
